Literature DB >> 25316796

Differential kinetics of human cytomegalovirus load and antibody responses in primary infection of the immunocompetent and immunocompromised host.

Giuseppe Gerna1, Daniele Lilleri2,1, Chiara Fornara1, Francesca Bruno1, Elisa Gabanti1, Ilaria Cane1, Milena Furione3, M Grazia Revello4.   

Abstract

The comparative long-term kinetics of human cytomegalovirus (HCMV) load and HCMV-specific antibody responses in the immunocompetent and immunocompromised solid-organ transplanted host during primary HCMV infection was investigated. In total, 40 immunocompetent subjects and 17 transplanted patients were examined for viral load as well as for IgG antibody responses to HCMV glycoproteins gH/gL/pUL128L, gH/gL and gB, and neutralizing antibodies in ARPE-19 epithelial cells and human fibroblasts. In parallel, the CD4(+) and CD8(+) HCMV-specific T-cell responses were determined by cytokine flow cytometry. Transplanted patients reached significantly higher viral DNA peaks, which persisted longer than in immunocompetent subjects. The ELISA-IgG responses to the pentamer, gH/gL and gB were significantly higher in primary infections of the immunocompetent until six months after onset, with the two antibody levels then overlapping from six to 12 months. Antibody levels neutralizing infection of epithelial cells were significantly higher in transplanted patients after six months, persisting for up to a year after transplantation. This trend was not observed for antibodies neutralizing infection of human fibroblasts, which showed higher titres in the immunocompetent over the entire one-year follow-up. In conclusion, in immunocompromised patients the viral load peak was much higher, while the neutralizing antibody response exceeded that detected in the immunocompetent host starting six months after onset of follow-up, often concomitantly with a lack of specific CD4(+) T cells. In this setting, the elevated antibody response occurred in the presence of differentiated follicular helper T cells in the blood, which decreased in number as did antibody titres upon reappearance of HCMV-specific CD4(+) T cells.
© 2015 The Authors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25316796     DOI: 10.1099/vir.0.070441-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity.

Authors:  Suzanne P M Welten; Anke Redeker; René E M Toes; Ramon Arens
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.

Authors:  Cody S Nelson; Ilona Baraniak; Daniele Lilleri; Matthew B Reeves; Paul D Griffiths; Sallie R Permar
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

3.  Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.

Authors:  Cody S Nelson; Jennifer A Jenks; Norbert Pardi; Matthew Goodwin; Hunter Roark; Whitney Edwards; Jason S McLellan; Justin Pollara; Drew Weissman; Sallie R Permar
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

Review 4.  The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV.

Authors:  Javier Carbone
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

5.  Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34+ Cells.

Authors:  Sebastian J Theobald; Sahamoddin Khailaie; Michael Meyer-Hermann; Valery Volk; Henning Olbrich; Simon Danisch; Laura Gerasch; Andreas Schneider; Christian Sinzger; Dirk Schaudien; Stefan Lienenklaus; Peggy Riese; Carlos A Guzman; Constanca Figueiredo; Constantin von Kaisenberg; Loukia M Spineli; Stephanie Glaesener; Almut Meyer-Bahlburg; Arnold Ganser; Michael Schmitt; Michael Mach; Martin Messerle; Renata Stripecke
Journal:  Front Immunol       Date:  2018-11-22       Impact factor: 7.561

6.  Murine Cytomegalovirus Exploits Olfaction To Enter New Hosts.

Authors:  Helen E Farrell; Clara Lawler; Cindy S E Tan; Kate MacDonald; Kimberley Bruce; Michael Mach; Nick Davis-Poynter; Philip G Stevenson
Journal:  MBio       Date:  2016-04-26       Impact factor: 7.867

Review 7.  Novel viral vectors in infectious diseases.

Authors:  Ian R Humphreys; Sarah Sebastian
Journal:  Immunology       Date:  2017-09-26       Impact factor: 7.397

Review 8.  Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.

Authors:  Michela Perotti; Laurent Perez
Journal:  Viruses       Date:  2019-12-28       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.